Yuhan inks $80.9M deal with Gilead Sciences for HIV drug ingredients
Yuhan sealed a $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human immunodeficiency virus (HIV), the Korean drugmaker announced in an electronic disclosure on Friday.